Feminising hormone therapy reduces testicular ACE-2 receptor expression: Implications for treatment or prevention of COVID-19 infection in men.


Journal

Andrologia
ISSN: 1439-0272
Titre abrégé: Andrologia
Pays: Germany
ID NLM: 0423506

Informations de publication

Date de publication:
Dec 2021
Historique:
revised: 22 06 2021
received: 05 05 2021
accepted: 24 06 2021
pubmed: 14 9 2021
medline: 4 11 2021
entrez: 13 9 2021
Statut: ppublish

Résumé

It has been proposed that men hospitalised with COVID-19 be treated with oestrogen or progesterone to improve COVID-19 outcomes. Transgender women (male-to-female) are routinely treated with oestrogen or oestrogen +progesterone for feminisation which provides a model for the effect of feminising hormones on testicular tissue. Our goal was to analyse differences in ACE-2 expression in testicles of trans-women taking oestrogen or oestrogen +progesterone. Orchiectomy specimens were collected from trans-women undergoing gender-affirming surgery, who were taking oestrogen or oestrogen+progesterone preoperatively. For controls, we used benign orchiectomy specimens from cis-gender men. All specimens were stained with H&E, Trichrome (fibrosis), insulin-like 3 antibody (Leydig cell) and ACE-2 IHC. Cells per high-powered field were counted by cell type (Leydig, Sertoli and Germ). Stain intensity was rated on a 0-2 scale. On immunohistochemistry staining for Leydig cells and ACE-2 staining, the oestrogen+progesterone cohort had fewer Leydig cells compared with controls. The oestrogen+progesterone cohort also had greater degree of tissue fibrosis compared with controls and the oestrogen cohort. This work supports the hopeful possibility that a short course of progesterone (or oestrogen+progesterone) could downregulate ACE-2 to protect men from COVID-19 infection.

Identifiants

pubmed: 34514615
doi: 10.1111/and.14186
pmc: PMC8646357
doi:

Substances chimiques

Estrogens 0
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14186

Subventions

Organisme : NINDS NIH HHS
ID : K02 NS046468
Pays : United States
Organisme : NIH HHS
ID : K26 OD010945
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS095894
Pays : United States

Informations de copyright

© 2021 Wiley-VCH GmbH.

Références

Clin Rev Allergy Immunol. 2020 Aug;59(1):78-88
pubmed: 32468411
Shock. 2016 Sep;46(3):239-48
pubmed: 27082314
J Appl Physiol (1985). 2020 Nov 1;129(5):1007-1008
pubmed: 33096966
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Exp Physiol. 2008 May;93(5):658-64
pubmed: 18192335
Transl Androl Urol. 2020 Mar;9(Suppl 2):S215-S226
pubmed: 32257862
Eur Heart J. 2020 May 14;41(19):1818-1820
pubmed: 32388547
Endocr Rev. 2007 Aug;28(5):521-74
pubmed: 17640948
Andrologia. 2021 Dec;53(11):e14186
pubmed: 34514615
Biol Sex Differ. 2010 Nov 05;1(1):6
pubmed: 21208466
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Natl Sci Rev. 2020 Sep;7(9):1414-1418
pubmed: 34192086
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Metabolism. 2020 Jul;108:154252
pubmed: 32353355
Clin Exp Immunol. 2003 May;132(2):265-70
pubmed: 12699415
Cells. 2020 Apr 09;9(4):
pubmed: 32283711
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Eur Urol Focus. 2020 Sep 15;6(5):1124-1129
pubmed: 32563676
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Ann Oncol. 2020 Aug;31(8):1040-1045
pubmed: 32387456
Fertil Steril. 2011 Jan;95(1):176-81
pubmed: 20674894
Chest. 2021 Jul;160(1):74-84
pubmed: 33621601
Front Immunol. 2018 Oct 04;9:2279
pubmed: 30337927
World J Mens Health. 2021 Jan;39(1):65-74
pubmed: 33151050
Ann N Y Acad Sci. 1999 Jun 22;876:426-9
pubmed: 10415638
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Mucosal Immunol. 2017 Sep;10(5):1097-1107
pubmed: 28401937
Am J Physiol Lung Cell Mol Physiol. 2020 Jun 1;318(6):L1280-L1281
pubmed: 32432918
J Appl Physiol (1985). 2020 Jun 1;128(6):1533-1538
pubmed: 32437244
J Clin Endocrinol Metab. 2009 Sep;94(9):3132-54
pubmed: 19509099
Sci Rep. 2015 Oct 19;5:15224
pubmed: 26477569
Endocr Rev. 1999 Aug;20(4):435-59
pubmed: 10453354
Clin Infect Dis. 2021 May 4;72(9):e240-e248
pubmed: 32697835
Cancers (Basel). 2020 Aug 18;12(8):
pubmed: 32824674
Biol Reprod. 2020 Aug 21;103(3):449-451
pubmed: 32427288
Crit Care. 2020 Dec 14;24(1):696
pubmed: 33317589
Life Sci. 2020 Sep 1;256:117905
pubmed: 32504757
JAMA Netw Open. 2020 May 1;3(5):e208292
pubmed: 32379329
Infect Dis Poverty. 2020 Apr 28;9(1):45
pubmed: 32345362
J Immunol. 2001 Aug 15;167(4):2060-7
pubmed: 11489988
Aging (Albany NY). 2020 Jun 5;12(11):10087-10098
pubmed: 32501810

Auteurs

John M Masterson (JM)

Department of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Chau Bui (C)

Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Yi Zhang (Y)

Biobank and Translational Research, Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Xiaopen Yuan (X)

Biobank and Translational Research, Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Carissa Huynh (C)

Biobank and Translational Research, Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Harneet Jawanda (H)

Biobank and Translational Research, Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Wohaib Hasan (W)

Biobank and Translational Research, Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Warren Tourtellotte (W)

Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Biobank and Translational Research, Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Daniel Luthringer (D)

Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Maurice M Garcia (MM)

Department of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH